Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 15/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NMBR | P28336 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13262679 | 0.93 | SIRT2 (0.48) | SIRT2NMBR | |
| SCHEMBL2034215 | 0.88 | SIRT2 (0.46) | SIRT2 | |
| SCHEMBL1038850 | 0.87 | SIRT2 (0.52) | SIRT2NMBRKDM4E | |
| SCHEMBL27351346 | 0.85 | SIRT2 (0.46) | SIRT2CYP11B1CYP11B2NMBR | |
| SCHEMBL877785 | 0.85 | SIRT2 (0.46) | SIRT2CYP11B1CYP11B2NMBR | |
| SCHEMBL27451583 | 0.84 | SIRT2 (0.46) | SIRT2CYP11B1CYP11B2NMBR | |
| Hydrochloric Acid SCHEMBL8892437 | 0.84 | SIRT2 (0.46) | SIRT2CYP11B1CYP11B2NMBR | |
| SCHEMBL9234830 | 0.83 | SIRT2 (0.45) | SIRT2CYP11B1CYP11B2NMBR | |
| SCHEMBL8892429 | 0.83 | SIRT2 (0.45) | SIRT2CYP11B1CYP11B2NMBR | |
| SCHEMBL30547297 | 0.83 | SIRT2 (0.45) | SIRT2CYP11B1CYP11B2NMBRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912687-B2 | 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof | Board of Trustees of the Southern Illinois University (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230382949-A1 | LINEAR APELIN RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-11-30 | — | — | US | disclosed |
| US-20230382949-A1 | LINEAR APELIN RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-11-30 | — | — | US | disclosed |
| CN-116710469-A | Linear Apelin receptor agonists | 赫帕雷斯治疗有限公司 | 2023-09-05 | — | — | CN | disclosed |
| EP-4225773-A1 | LINEAR APELIN RECEPTOR AGONISTS | Heptares Therapeutics Limited (GB) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022079428-A1 | LINEAR APELIN RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022079428-A1 | LINEAR APELIN RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-04-21 | — | — | WO | disclosed |
| EP-3204408-B1 | STABLE GLP-1 BASED GLP-1/GLUCAGON RECEPTOR CO-AGONISTS | NOVO NORDISK AS (DK) | 2020-05-06 | — | — | EP | disclosed |
| EP-3204408-B1 | STABLE GLP-1 BASED GLP-1/GLUCAGON RECEPTOR CO-AGONISTS | NOVO NORDISK AS (DK) | 2020-05-06 | — | — | EP | disclosed |
| EP-3390357-A1 | BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | Merck Sharp & Dohme Corp. (US) | 2018-10-24 | — | — | EP | disclosed |
| EP-0944387-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-09-29 | — | — | EP | disclosed |
| EP-0873123-A4 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIV PITTSBURGH (US) | 1999-02-03 | — | — | EP | disclosed |
| EP-0873123-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1998-10-28 | — | — | EP | disclosed |
| WO-1997027852-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-08-07 | — | — | WO | disclosed |
| WO-1997017070-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1997-05-15 | — | — | WO | disclosed |
| US-5428160-A | Condensation of imidazole derivative with cyano- or halo-substituted benzene derivative containing leaving group esterified with carboxylic or sulfonic acid | CIBA-GEIGY CORPORATION (US) | 1995-06-27 | — | — | US | disclosed |
| EP-0165904-B1 | SUBSTITUTED BICYCLE COMPOUNDS | CIBA-GEIGY AG (CH) | 1991-04-10 | — | — | EP | disclosed |
| US-4889861-A | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors | CIBA-GEIGY CORP. (US) | 1989-12-26 | — | — | US | disclosed |
| US-4728645-A | THROMBOXANE SYNTHETASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1988-03-01 | — | — | US | disclosed |
| EP-0165904-A2 | Substituted bicycle compounds | CIBA-GEIGY AG (CH) | 1985-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382949-A1 | LINEAR APELIN RECEPTOR AGONISTS | APLNR, MTNR1A, EDNRA | SIRT2 4152/4885CYP11B1 965/4885CYP11B2 1390/4885 |
| US-11912687-B2 | 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof | SSTR4, SSTR5, SSTR3 | SIRT2 1700/4885CYP11B1 738/4885CYP11B2 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.